Excessive Phlebotomy in Cardiac Surgical Care Leads to Anemia
|
By LabMedica International staff writers Posted on 01 Apr 2015 |

Image: Phlebotomy or venipuncture performed to obtain blood for laboratory tests (Photo courtesy of Sweet Water Health and Education).
Laboratory testing among patients undergoing cardiac surgery can lead to excessive bloodletting, which can increase the risk of developing hospital-acquired anemia and the need for blood transfusion.
Health care providers are seldom aware of the frequency and volume of phlebotomy for laboratory testing, bloodletting that often leads to nosocomial anemia. The frequency of laboratory testing in patients undergoing cardiac surgery, and the cumulative phlebotomy volume from time of initial surgical consultation to hospital discharge has been investigated.
Medical teams at the Cleveland Clinic (Cleveland, OH, USA) examined every laboratory test from 1,894 patients who underwent cardiac surgery from January to June 2012. The number and type of blood tests performed were recorded from the time patients met their surgeons until hospital discharge. The scientists then tallied up the total amount of blood taken from each patient. Phlebotomy volume was estimated separately for the intensive care unit (ICU), hospital floors, and cumulatively.
A total of 221,498 laboratory tests were performed, averaging 115 tests per patient. The most frequently performed tests were 88,068 blood gas analyses, 39,535 coagulation tests, 30,421 complete blood counts, and 29,374 metabolic panels. Phlebotomy volume differed between ICU and hospital floors, with median volumes of 332 mL and 118 mL, respectively. Cumulative median volume for the entire hospital stay was 454 mL. More complex procedures were associated with higher overall phlebotomy volume than isolated procedures. Foe combined coronary artery bypass grafting (CABG) and valve procedure, the median volume was 653 mL versus 448 mL for isolated CABG and 338 mL for isolated valve procedures.
Colleen G. Koch, MD, MS, MBA, the lead author of the study said, “We were astonished by the amount of blood taken from our patients for laboratory testing. Total phlebotomy volumes approached one to two units of red blood cells, which is roughly equivalent to one to two cans of carbonated beverage. Patients should feel empowered to ask their doctors whether a specific test is necessary, such as: What is the indication for the test? Will it change my care? And if so, do you need to do it every day? They should inquire whether smaller volume test tubes could be used for the tests that are deemed necessary. Every attempt should be made to conserve the patient's own blood, every drop of blood counts.” The study was published in the March 2015 issue of the journal the Annals of Thoracic Surgery.
Related Links:
Cleveland Clinic
Health care providers are seldom aware of the frequency and volume of phlebotomy for laboratory testing, bloodletting that often leads to nosocomial anemia. The frequency of laboratory testing in patients undergoing cardiac surgery, and the cumulative phlebotomy volume from time of initial surgical consultation to hospital discharge has been investigated.
Medical teams at the Cleveland Clinic (Cleveland, OH, USA) examined every laboratory test from 1,894 patients who underwent cardiac surgery from January to June 2012. The number and type of blood tests performed were recorded from the time patients met their surgeons until hospital discharge. The scientists then tallied up the total amount of blood taken from each patient. Phlebotomy volume was estimated separately for the intensive care unit (ICU), hospital floors, and cumulatively.
A total of 221,498 laboratory tests were performed, averaging 115 tests per patient. The most frequently performed tests were 88,068 blood gas analyses, 39,535 coagulation tests, 30,421 complete blood counts, and 29,374 metabolic panels. Phlebotomy volume differed between ICU and hospital floors, with median volumes of 332 mL and 118 mL, respectively. Cumulative median volume for the entire hospital stay was 454 mL. More complex procedures were associated with higher overall phlebotomy volume than isolated procedures. Foe combined coronary artery bypass grafting (CABG) and valve procedure, the median volume was 653 mL versus 448 mL for isolated CABG and 338 mL for isolated valve procedures.
Colleen G. Koch, MD, MS, MBA, the lead author of the study said, “We were astonished by the amount of blood taken from our patients for laboratory testing. Total phlebotomy volumes approached one to two units of red blood cells, which is roughly equivalent to one to two cans of carbonated beverage. Patients should feel empowered to ask their doctors whether a specific test is necessary, such as: What is the indication for the test? Will it change my care? And if so, do you need to do it every day? They should inquire whether smaller volume test tubes could be used for the tests that are deemed necessary. Every attempt should be made to conserve the patient's own blood, every drop of blood counts.” The study was published in the March 2015 issue of the journal the Annals of Thoracic Surgery.
Related Links:
Cleveland Clinic
Latest Clinical Chem. News
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
Channels
Clinical Chemistry
view channel
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read moreMolecular Diagnostics
view channel
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more
Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
Circulating tumor-derived DNA (ctDNA) is often present at very low levels in plasma, making cancer detection and monitoring through liquid biopsy technically challenging. Background cell-free DNA from... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







